SNPHF - Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd.
Grand Front Osaka Tower A
4-20 Ofuka-cho Kita-ku
Osaka 530-8552
Japan
81 6 7664 8621
https://www.santen.com
Sector(es): Healthcare
Sector: Drug Manufacturers—General
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Takeshi Ito | Pres, CEO & Representative Director | N/A | N/A | 1959 |
| Mr. Kazuo Koshiji | Chief Financial Officer & Chief Risk Officer | N/A | N/A | N/A |
| Ms. Rie Nakajima | COO & Corp. Officer | N/A | N/A | N/A |
| Mr. Minori Hara | Chief Digital & Information Officer | N/A | N/A | N/A |
| Ms. Kaori Itagaki | Gen. Mang. of Investor Relations Group | N/A | N/A | N/A |
| Ms. Mika Masunari | Gen. Counsel & Chief Compliance Officer | N/A | N/A | N/A |
| Ms. Nobuko Kato | Chief Communications Officer | N/A | N/A | N/A |
| Mr. Satoshi Suzuki | Sr. Corp. Officer & Head of Corp. Devel. Division | N/A | N/A | N/A |
| Mr. Shinichi Teramachi | Corp. Officer, Head of Sales Department & Japan Sales and Marketing Division | N/A | N/A | N/A |
| Mr. Ippei Kurihara | Corp. Officer and Head of Marketing Department, Japan Bus., Japan Sales & Marketing Division | N/A | N/A | N/A |
Descripción
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia. In addition, it provides STN1012701, which is in Phase III clinical trial to treat myopia; STN1013800, which is in clinical preparation to treat ptosis; STN6000100, which is in clinical preparation to treat retinitis pigmentosa; STN1013400, which is in Phase I clinical trial to treat myopia; and STN1012700, which is in Phase I clinical trial to treat myopia. Further, it offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Gobierno corporativo
El ISS Governance QualityScore de Santen Pharmaceutical Co., Ltd., a día 1 de junio de 2023, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 2; Compensación: 1.
